- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease | 470 | GlobeNewswire (Europe) | Investigational Oral Candidate JOTROL Addresses a Parkinson's Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences... ► Artikel lesen | |
| Mi | Jupiter Neurosciences: EPS verfehlt Schätzungen - Umsatz schlechter als erwartet | 2 | Investing.com Deutsch | ||
| 26.05. | D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. in Connection with its ~$2 Million Registered Direct Offering | 360 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system... ► Artikel lesen | |
| JUPITER NEUROSCIENCES Aktie jetzt für 0€ handeln | |||||
| 21.05. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering | 5 | GlobeNewswire (USA) | ||
| 20.05. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering | 4 | GlobeNewswire (USA) | ||
| 20.05. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million | 1 | GlobeNewswire (USA) | ||
| 20.05. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech | 592 | GlobeNewswire (Europe) | Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May... ► Artikel lesen | |
| 14.05. | JUPITER NEUROSCIENCES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.04. | Centri: Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14 | 469 | Newsfile | Jupiter, Florida--(Newsfile Corp. - April 13, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform... ► Artikel lesen | |
| 07.04. | Jupiter Neurosciences stärkt Beirat für Expansion im Consumer-Bereich | 4 | Investing.com Deutsch | ||
| 07.04. | Jupiter Neurosciences adds advisors for consumer product expansion | 1 | Investing.com | ||
| 07.04. | Jupiter Neurosciences verstärkt Beirat für Produktlinie Nugevia | 3 | Investing.com Deutsch | ||
| 07.04. | Jupiter Neurosciences adds advisors for consumer product line | 1 | Investing.com | ||
| 01.04. | JUPITER NEUROSCIENCES, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 01.04. | JUPITER NEUROSCIENCES, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 25.02. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago | 1 | GlobeNewswire (USA) | ||
| 23.02. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution | 1 | GlobeNewswire (USA) | ||
| 20.02. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.02. | JUPITER NEUROSCIENCES, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEVA | 29,800 | 0,00 % | Teva Pharmaceutical Industries Ltd: Teva to Present at the Goldman Sachs Global Healthcare Conference | PARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 4,512 | -0,44 % | Quantum BioPharma Provides Corporate Update | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, June 01, 2026... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 10,745 | +1,66 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 ... | Real-world analysis of three years of closed claims data from Symphony Health focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgia Data... ► Artikel lesen | |
| MEDPACE | 389,60 | +0,36 % | Zelluna ASA: Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial | Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy productPartnership follows submission of the Clinical Trial Application (CTA) to the MHRA... ► Artikel lesen | |
| ALTIMMUNE | 2,580 | -0,19 % | Citizens reiterates Altimmune stock rating on fibrosis trial data | ||
| LIGAND PHARMACEUTICALS | 191,00 | -3,54 % | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement | $15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty... ► Artikel lesen | |
| JAGUAR HEALTH | 3,220 | -1,53 % | Jaguar Health, Inc.: Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders | Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance ("botanical drug") derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulation... ► Artikel lesen | |
| XORTX THERAPEUTICS | 1,924 | +1,68 % | XORTX Therapeutics Inc.: XORTX Meets Nasdaq Continued Listing Requirements | CALGARY, Alberta, April 21, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 66,00 | 0,00 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance | Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-yearPurified Cortrophin- Gel net revenues of $75.1 million, an increase of 42.1% year-over-yearQuarterly GAAP net income available... ► Artikel lesen | |
| SOLIGENIX | 0,830 | +0,57 % | SOLIGENIX, INC. - 8-K, Current Report | ||
| CNBX PHARMACEUTICALS | - | - | CNBX Pharmaceuticals Inc. - 10-Q, Quarterly Report | ||
| KALA BIO | 2,190 | -0,45 % | XFRA 27F: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKALA BIO INC. O.N.... ► Artikel lesen | |
| THERIVA BIOLOGICS | 0,284 | 0,00 % | Theriva Biologics, Inc.: Theriva Biologics Reports First Quarter 2026 Operational Highlights and Financial Results | - Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) -
- Additional data from VIRAGE Phase... ► Artikel lesen | |
| HEPION PHARMACEUTICALS | 0,073 | -11,10 % | Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma | Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion's strategic shift to advancing clinically proven... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,690 | 0,00 % | Weekly Buzz: Sanofi, Regeneron Pharmaceuticals Get FDA Nod; It's A No For AbbVie, Grace Therapeutics; Eli Lilly Acquires Kelonia | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning... ► Artikel lesen |
Das Unternehmen JUPITER NEUROSCIENCES INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,005 (+1,91 %) liegt der Kurs bei 0,267 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JUPITER NEUROSCIENCES INC finden Sie auf Wallstreet Online.